Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
SMC
Record ID 32018001092
English
Authors' objectives:
To assess clinical and cost effectiveness.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2295/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Adult
- Adolescent
- Child
- Neoplasms
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.